Abstract:In this work, a novel manganese‐modified aluminum adjuvant (Mn‐Al) is designed. Mn‐Al adjuvant improved the ability of conventional aluminum‐based adjuvant in enhancing cellular immune responses. It can promote more effective and durable antigen‐specific antibodies titers as well as potent antigen‐specific cellular immune responses and show better protective effects in melanoma vaccine and HPV vaccine applications. Aluminum adjuvants remain the most commonly used vaccine adjuvants. Being rather effective in triggering humoral immunity, however, aluminum adjuvants usually show limited abilities in activating cellular immunities. Herein, by adding manganese ions during the preparation of aluminum adjuvant, a manganese‐modified aluminum (Mn‐Al) adjuvant is obtained, which can effectively stimulate both humoral and cellular immune responses. Such Mn‐Al adjuvant can enhance antigen adsorption and promote antigen internalization by dendritic cells (DCs). Subsequently, the released Mn2+ can activate the cyclic guanosine monophosphate–adenosine monophosphate synthase‐stimulator of interferon genes pathway to further promote DC activation. When combines with the model antigen ovalbumin (OVA), the Mn‐Al‐adjuvantes vaccine can induce high levels of antigen‐specific antibody titers and high proportions of antigen‐specific cytotoxic T cells in vivo. Moreover, the Mn‐Al‐adjuvanted vaccine elicited stronger antigen‐specific humoral and cellular immune responses than high‐dose of the aluminum‐based adjuvant. Additionally, immunization of mice with OVA in the presence of the Mn‐Al adjuvant significantly inhibited the growth of B16‐OVA tumors. Furthermore, when formulated with human papillomavirus antigens, Mn‐Al‐adjuvanted vaccines show better in vivo vaccination performance than aluminum‐adjuvanted vaccines. Therefore, the manganese‐modified aluminum adjuvant may thus become a new vaccine adjuvant with the potential to replace conventional aluminum adjuvants.

Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine

pH-Sensitive and Biodegradable Mn3(PO4)2·3H2O Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 Vaccine to Induce Potent and Broad-Spectrum Immunity

Enhancing Dendritic Cell Activation Through Manganese-Coated Nanovaccine Targeting the cGAS-STING Pathway

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant

A Mn Al double adjuvant nanovaccine to induce strong humoral and cellular immune responses

Manganese nanodepot augments host immune response against coronavirus

Manganese Salts Function As Potent Adjuvants

Manganese-based nanoadjuvants for enhancement of immune effect of DNA vaccines

Manganese‐Modified Aluminum Adjuvant Enhances both Humoral and Cellular Immune Responses

Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus

STING agonist-loaded mesoporous manganese-silica nanoparticles for vaccine applications

A Unique Combination of Mn2+ and Aluminum Adjuvant Acted the Synergistic Effect

Proanthocyanidins-based Adjuvant for Enhanced Immune Responses of SARS-CoV-2 Subunit Vaccine

Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo

Universal selenium nanoadjuvant with immunopotentiating and redox-shaping activities inducing high-quality immunity for SARS-CoV-2 vaccine

Manganese‐Based Nanoparticle Vaccine for Combating Fatal Bacterial Pneumonia

Manganese-based Microcrystals Equipped with Ythdf1-targeted Biomimetic Nanovaccines for Reinforced Dendritic Cell Spatiotemporal Orchestration

Synergistic Glutathione Depletion and STING Activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy

The Manganese Salt (MnJ) Functions as A Potent Universal Adjuvant

Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19

Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy.